{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:07:40Z","timestamp":1788959260783,"version":"build-2803163510"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00986-0","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:33:02Z","timestamp":1788957182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics"],"prefix":"10.1186","volume":"14","author":[{"given":"Ruiyi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-677X","authenticated-orcid":false,"given":"Kan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"11","key":"986_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41585-024-00876-w","volume":"21","author":"C Liao","year":"2024","unstructured":"Liao C, Hu L, Zhang Q. Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma. Nat Rev Urol. 2024;21(11):662\u201375. https:\/\/doi.org\/10.1038\/s41585-024-00876-w.","journal-title":"Nat Rev Urol"},{"key":"986_CR2","doi-asserted-by":"publisher","unstructured":"Haase VH. The VHL\/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 2006;69(8):1302\u201307. https:\/\/doi.org\/10.1038\/sj.ki.5000221.","DOI":"10.1038\/sj.ki.5000221"},{"issue":"5","key":"986_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.hoc.2023.04.011","volume":"37","author":"NH Shirole","year":"2023","unstructured":"Shirole NH, Kaelin WG. Von-Hippel Lindau and hypoxia-inducible Factor at the center of renal cell carcinoma biology. Hematol Oncol Clin N Am. 2023;37(5):809\u201325. https:\/\/doi.org\/10.1016\/j.hoc.2023.04.011.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"11","key":"986_CR4","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1007\/s12094-025-03954-6","volume":"27","author":"Q Tian","year":"2025","unstructured":"Tian Q, Tang W, Cao X. Mutational landscape and clinical implications of VHL in clear cell renal cell carcinoma: a multi-dataset analysis of 1377. Clin Transl Oncol. 2025;27(11):4260\u201368. https:\/\/doi.org\/10.1007\/s12094-025-03954-6.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"986_CR5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","volume":"18","author":"AM Nargund","year":"2017","unstructured":"Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, et al. The SWI\/SNF protein PBRM1 restrains VHL-Loss-driven clear cell renal cell carcinoma. Cell Rep. 2017;18(12):2893\u2013906. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.074.","journal-title":"Cell Rep"},{"issue":"5","key":"986_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1073\/pnas.1619726114","volume":"114","author":"W Gao","year":"2017","unstructured":"Gao W, Li W, Xiao T, Liu XS, Kaelin WG. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma. Proc Natl Acad Sci USA. 2017;114(5):1027\u201332. https:\/\/doi.org\/10.1073\/pnas.1619726114.","journal-title":"Proc Natl Acad Sci USA"},{"key":"986_CR7","doi-asserted-by":"publisher","first-page":"1713830","DOI":"10.3389\/fcell.2025.1713830","volume":"13","author":"M Johnson","year":"2026","unstructured":"Johnson M, Turcotte S. The fall of the genome protectors triad: PBRM1, SETD2, and BAP1\u2019s impact on metabolism and immunity in clear cell renal cell carcinoma. Front Cell Dev Biol. 2026;13:1713830. https:\/\/doi.org\/10.3389\/fcell.2025.1713830.","journal-title":"Front Cell Dev Biol"},{"key":"986_CR8","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43\u201349. https:\/\/doi.org\/10.1038\/nature12222.","DOI":"10.1038\/nature12222"},{"issue":"3","key":"986_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell. 2018;173(3):595\u2013610.e11. https:\/\/doi.org\/10.1016\/j.cell.2018.03.043.","journal-title":"Cell"},{"issue":"4","key":"986_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","volume":"17","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. Nature Publishing Group. 2021;17(4):245\u201361. https:\/\/doi.org\/10.1038\/s41581-020-00359-2.","journal-title":"Nat Rev Nephrol"},{"issue":"10451","key":"986_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. London, England. 2024;404(10451):476\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(24)00917-6.","journal-title":"Lancet"},{"issue":"6","key":"986_CR12","doi-asserted-by":"publisher","first-page":"300060520924265","DOI":"10.1177\/0300060520924265","volume":"48","author":"X Song","year":"2020","unstructured":"Song X, Tian Y-N, Li H, Liu B, Zhang A-L, Hong Y. Research progress on advanced renal cell carcinoma. J Int Med Res. 2020;48(6):300060520924265. https:\/\/doi.org\/10.1177\/0300060520924265.","journal-title":"J Int Med Res"},{"issue":"3","key":"986_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","volume":"58","author":"T Yu","year":"2017","unstructured":"Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J. 2017;58(3):489\u201396. https:\/\/doi.org\/10.3349\/ymj.2017.58.3.489.","journal-title":"Yonsei Med J"},{"issue":"7","key":"986_CR14","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms21072532","volume":"21","author":"A Deleuze","year":"2020","unstructured":"Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, et al. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci. 2020;21(7):2532. https:\/\/doi.org\/10.3390\/ijms21072532.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"986_CR15","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","volume":"28","author":"J Fallah","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA approval summary: Belzutifan for Von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022;28(22):4843\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1054.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"986_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391(8):710\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2313906.","journal-title":"N Engl J Med"},{"issue":"5","key":"986_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025;26(5):571\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(25)00099-3.","journal-title":"The Lancet Oncol"},{"issue":"22","key":"986_CR18","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","volume":"30","author":"J Fallah","year":"2024","unstructured":"Fallah J, Heiss BL, Joeng H-K, Weinstock C, Gao X, Pierce WF, et al. FDA approval summary: belzutifan for patients with advanced renal cell carcinoma. Clin Cancer Res. 2024;30(22):5003\u201308. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1199.","journal-title":"Clin Cancer Res"},{"issue":"7627","key":"986_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, et al. On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models. Nature. 2016;539(7627):107\u201311. https:\/\/doi.org\/10.1038\/nature19795.","journal-title":"Nature"},{"key":"986_CR20","doi-asserted-by":"publisher","unstructured":"Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, et al. Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc Natl Acad Sci USA. 2022;119(14):e2120403119. https:\/\/doi.org\/10.1073\/pnas.2120403119.","DOI":"10.1073\/pnas.2120403119"},{"issue":"7","key":"986_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1158\/2159-8290.CD-24-1378","volume":"15","author":"NH Shirole","year":"2025","unstructured":"Shirole NH, Kesar D, Lee Y, Goodale A, Syamala S, Kukreja S, et al. Requirement for cyclin D1 underlies cell-autonomous HIF2 dependence in kidney cancer. Cancer Discov. 2025;15(7):1484\u2013504. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1378.","journal-title":"Cancer Discov"},{"issue":"4","key":"986_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney KD, Ma Y, Diaz de Leon A, Christie A, Xie Z, Woolford L, et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin Cancer Res. 2020;26(4):793\u2013803. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1459.","journal-title":"Clin Cancer Res"},{"issue":"7627","key":"986_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112\u201317. https:\/\/doi.org\/10.1038\/nature19796.","journal-title":"Nature"},{"issue":"7","key":"986_CR24","doi-asserted-by":"publisher","first-page":"200109","DOI":"10.1098\/rsob.200109","volume":"10","author":"G Minervini","year":"2020","unstructured":"Minervini G, Pennuto M, Tosatto SCE. The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer. Open Biol. 2020;10(7):200109. https:\/\/doi.org\/10.1098\/rsob.200109.","journal-title":"Open Biol"},{"issue":"20","key":"986_CR25","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1093\/nar\/gkad796","volume":"51","author":"S Park","year":"2023","unstructured":"Park S, Cho JH, Kim J-H, Park M, Park S, Kim S-Y, et al. Hypoxia stabilizes SETDB1 to maintain genome stability. Nucleic Acids Res. 2023;51(20):11178\u201396. https:\/\/doi.org\/10.1093\/nar\/gkad796.","journal-title":"Nucleic Acids Res"},{"issue":"6399","key":"986_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aap8411","volume":"361","author":"J Zhang","year":"2018","unstructured":"Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018;361(6399):290\u201395. https:\/\/doi.org\/10.1126\/science.aap8411.","journal-title":"Science"},{"issue":"6","key":"986_CR27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.molcel.2020.01.009","volume":"77","author":"X Liu","year":"2020","unstructured":"Liu X, Simon JM, Xie H, Hu L, Wang J, Zurlo G, et al. Genome-wide screening identifies SFMBT1 as an oncogenic driver in cancer with VHL loss. Mol Cell. 2020;77(6):1294\u2013306.e5. https:\/\/doi.org\/10.1016\/j.molcel.2020.01.009.","journal-title":"Mol Cell"},{"issue":"3","key":"986_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/2159-8290.CD-19-0837","volume":"10","author":"L Hu","year":"2020","unstructured":"Hu L, Xie H, Liu X, Potjewyd F, James LI, Wilkerson EM, et al. TBK1 is a synthetic lethal target in cancer with VHL loss. Cancer Discov. 2020;10(3):460\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0837.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"6","key":"986_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5483\/BMBRep.2015.48.6.080","volume":"48","author":"KC Park","year":"2015","unstructured":"Park KC, Lee DC, Yeom YI. NDRG3-mediated lactate signaling in hypoxia. BMB Rep. 2015;48(6):301\u201302. https:\/\/doi.org\/10.5483\/BMBRep.2015.48.6.080.","journal-title":"BMB Rep"},{"issue":"4","key":"986_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15586\/jkcvhl.v11i4.355","volume":"11","author":"H Kanno","year":"2024","unstructured":"Kanno H, Nakahara K, Yamada S, Fujii S, Murata H, Yamamoto T, et al. Relationship between ZHX2 expression and VHL gene alteration in VHL-associated and sporadic hemangioblastomas of the central nervous system. J Kidney Cancer VHL. 2024;11(4):39\u201347. https:\/\/doi.org\/10.15586\/jkcvhl.v11i4.355.","journal-title":"J Kidney Cancer VHL"},{"issue":"11","key":"986_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/2326-6066.CIR-21-0543","volume":"9","author":"H Hu","year":"2021","unstructured":"Hu H, Khodadadi-Jamayran A, Dolgalev I, Cho H, Badri S, Chiriboga LA, et al. Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity. Cancer Immunol Res. 2021;9(11):1298\u2013315. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0543.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"986_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-020-2561-6","volume":"11","author":"N Cao","year":"2020","unstructured":"Cao N, Yu Y, Zhu H, Chen M, Chen P, Zhuo M, et al. SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression. Cell Death Dis. 2020;11(5):351. https:\/\/doi.org\/10.1038\/s41419-020-2561-6.","journal-title":"Cell Death Dis"},{"key":"986_CR33","doi-asserted-by":"publisher","unstructured":"Zhang C, Yu M, Hepperla AJ, Zhang Z, Raj R, Zhong H, et al. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis. J Clin Invest. 2024;134(8):e175703. https:\/\/doi.org\/10.1172\/JCI175703.","DOI":"10.1172\/JCI175703"},{"issue":"35","key":"986_CR34","doi-asserted-by":"publisher","first-page":"21441","DOI":"10.1073\/pnas.2000516117","volume":"117","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Thakkar KN, Zhao H, Broughton J, Li Y, Seoane JA, et al. The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc Natl Acad Sci USA. 2020;117(35):21441\u201349. https:\/\/doi.org\/10.1073\/pnas.2000516117.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"986_CR35","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1073\/pnas.0436037100","volume":"100","author":"AV Kuznetsova","year":"2003","unstructured":"Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, Sanchez Y, et al. von Hippel-Lindau Protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA. 2003;100(5):2706\u201311. https:\/\/doi.org\/10.1073\/pnas.0436037100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"986_CR36","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/MCB.01231-07","volume":"28","author":"O Mikhaylova","year":"2008","unstructured":"Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH, et al. The von Hippel-Lindau tumor suppressor protein and egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol. 2008;28(8):2701\u201317. https:\/\/doi.org\/10.1128\/MCB.01231-07.","journal-title":"Mol Cell Biol"},{"issue":"21","key":"986_CR37","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1158\/1078-0432.CCR-09-3416","volume":"16","author":"Y Yi","year":"2010","unstructured":"Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, et al. von Hippel-Lindau-dependent Patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. Clin Cancer Res. 2010;16(21):5142\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3416.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"986_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-025-07623-y","volume":"16","author":"M Akuma","year":"2025","unstructured":"Akuma M, Kim M, Zhu C, Wiljer E, Gaudreau-Lapierre A, Patterson LD, et al. Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma. Cell Death Dis. 2025;16(1):307. https:\/\/doi.org\/10.1038\/s41419-025-07623-y.","journal-title":"Cell Death Dis"},{"key":"986_CR39","doi-asserted-by":"publisher","unstructured":"Wei R, Ren X, Kong H, Lv Z, Chen Y, Tang Y, et al. Rb1\/Rbl1\/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma. JCI Insight. 2019;4(22):e127889, 127889. https:\/\/doi.org\/10.1172\/jci.insight.127889.","DOI":"10.1172\/jci.insight.127889"},{"key":"986_CR40","doi-asserted-by":"publisher","unstructured":"Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA, Perrimon N, et al. HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species. Sci Signal. 2019;12(601):eaay0482. https:\/\/doi.org\/10.1126\/scisignal.aay0482.","DOI":"10.1126\/scisignal.aay0482"},{"issue":"12","key":"986_CR41","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/MCB.00067-16","volume":"36","author":"F Okumura","year":"2016","unstructured":"Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, et al. Parallel regulation of von Hippel-Lindau disease by pVHL-mediated degradation of B-Myb and hypoxia-inducible factor \u03b1. Mol Cell Biol. 2016;36(12):1803\u201317. https:\/\/doi.org\/10.1128\/MCB.00067-16.","journal-title":"Mol Cell Biol"},{"key":"986_CR42","doi-asserted-by":"publisher","unstructured":"Zhou L, Yang H. The von Hippel-Lindau tumor suppressor protein promotes c-cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One. 2011;6(9):e23936. https:\/\/doi.org\/10.1371\/journal.pone.0023936.","DOI":"10.1371\/journal.pone.0023936"},{"key":"986_CR43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3389\/fonc.2020.00703","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu Z, Li L, Yi Z, Duan H, Lu R, Li C, et al. Overexpression of EGFR and TGF\u03b1 in von Hippel-Lindau-related central nervous system Hemangioblastomas. Front Oncol. 2020;10:703. https:\/\/doi.org\/10.3389\/fonc.2020.00703.","journal-title":"Front Oncol"},{"issue":"14","key":"986_CR44","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1074\/jbc.M115.694562","volume":"291","author":"P Heir","year":"2016","unstructured":"Heir P, Srikumar T, Bikopoulos G, Bunda S, Poon BP, Lee JE, et al. Oxygen-dependent regulation of erythropoietin receptor turnover and signaling. J Biol Chem. 2016;291(14):7357\u201372. https:\/\/doi.org\/10.1074\/jbc.M115.694562.","journal-title":"J Biol Chem"},{"issue":"49","key":"986_CR45","doi-asserted-by":"publisher","first-page":"42027","DOI":"10.1074\/jbc.M111.303222","volume":"286","author":"K Anderson","year":"2011","unstructured":"Anderson K, Nordquist KA, Gao X, Hicks KC, Zhai B, Gygi SP, et al. Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J Biol Chem. 2011;286(49):42027\u201336. https:\/\/doi.org\/10.1074\/jbc.M111.303222.","journal-title":"J Biol Chem"},{"issue":"6302","key":"986_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aad5755","volume":"353","author":"J Guo","year":"2016","unstructured":"Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, et al. pVHL suppresses kinase activity of akt in a proline-hydroxylation-dependent manner. Science. 2016;353(6302):929\u201332. https:\/\/doi.org\/10.1126\/science.aad5755.","journal-title":"Science"},{"issue":"3","key":"986_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2015.03.011","volume":"161","author":"DC Lee","year":"2015","unstructured":"Lee DC, Sohn HA, Park Z-Y, Oh S, Kang YK, Lee K-M, et al. A lactate-induced response to hypoxia. Cell. 2015;161(3):595\u2013609. https:\/\/doi.org\/10.1016\/j.cell.2015.03.011.","journal-title":"Cell"},{"issue":"6","key":"986_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s42255-022-00593-x","volume":"4","author":"S Li","year":"2022","unstructured":"Li S, Li W, Yuan J, Bullova P, Wu J, Zhang X, et al. Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome. Nat Metab. 2022;4(6):739\u201358. https:\/\/doi.org\/10.1038\/s42255-022-00593-x.","journal-title":"Nat Metab"},{"issue":"1\u20133","key":"986_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0014-5793(03)01392-9","volume":"556","author":"HAR Bluyssen","year":"2004","unstructured":"Bluyssen HAR, Lolkema MPJK, van Beest M, Boone M, Snijckers CMJT, Los M, et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 2004;556(1\u20133):137\u201342. https:\/\/doi.org\/10.1016\/s0014-5793(03)01392-9.","journal-title":"FEBS Lett"},{"issue":"8","key":"986_CR50","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/MCB.24.8.3251-3261.2004","volume":"24","author":"NH Stickle","year":"2004","unstructured":"Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol. 2004;24(8):3251\u201361. https:\/\/doi.org\/10.1128\/MCB.24.8.3251-3261.2004.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"986_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-05-2560","volume":"66","author":"G Kurban","year":"2006","unstructured":"Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 2006;66(3):1313\u201319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2560.","journal-title":"Cancer Res"},{"issue":"18","key":"986_CR52","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1074\/jbc.M611648200","volume":"282","author":"A Grosfeld","year":"2007","unstructured":"Grosfeld A, Stolze IP, Cockman ME, Pugh CW, Edelmann M, Kessler B, et al. Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor. J Biol Chem. 2007;282(18):13264\u201369. https:\/\/doi.org\/10.1074\/jbc.M611648200.","journal-title":"J Biol Chem"},{"issue":"24","key":"986_CR53","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/onc.2016.495","volume":"36","author":"E Hasanov","year":"2017","unstructured":"Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, et al. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017;36(24):3450\u201363. https:\/\/doi.org\/10.1038\/onc.2016.495.","journal-title":"Oncogene"},{"issue":"12","key":"986_CR54","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1681\/ASN.2010040345","volume":"21","author":"J Xu","year":"2010","unstructured":"Xu J, Li H, Wang B, Xu Y, Yang J, Zhang X, et al. VHL inactivation induces HEF1 and Aurora kinase a. J Am Soc Nephrol. 2010;21(12):2041\u201346. https:\/\/doi.org\/10.1681\/ASN.2010040345.","journal-title":"J Am Soc Nephrol"},{"key":"986_CR55","doi-asserted-by":"publisher","unstructured":"Martin B, Chesnel F, Delcros J-G, Jouan F, Couturier A, Dugay F, et al. Identification of pVHL as a novel substrate for aurora-A in clear cell renal cell carcinoma (ccRCC). PLoS One. 2013;8(6):e67071. https:\/\/doi.org\/10.1371\/journal.pone.0067071.","DOI":"10.1371\/journal.pone.0067071"},{"issue":"2","key":"986_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/bbrc.1999.1347","volume":"263","author":"H Okuda","year":"1999","unstructured":"Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun. 1999;263(2):491\u201397. https:\/\/doi.org\/10.1006\/bbrc.1999.1347.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"986_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11033-025-10272-1","volume":"52","author":"AF Schurr","year":"2025","unstructured":"Schurr AF, Dave CS, Shah PJ, Meth JL, Jaramillo AS, Bartley K, et al. Protein kinase C iota (PKC\u03b9) and pVHL are both needed for lysosomal degradation of \u03b15 integrin in renal carcinoma cells. Mol Biol Rep. 2025;52(1):177. https:\/\/doi.org\/10.1007\/s11033-025-10272-1.","journal-title":"Mol Biol Rep"},{"key":"986_CR58","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-19-1525","volume-title":"TBK1 activation by VHL loss in renal cell carcinoma: a novel HIF-Independent vulnerability","author":"Z Bakouny","year":"2020","unstructured":"Bakouny Z, Barbie DA. TBK1 activation by VHL loss in renal cell carcinoma: a novel HIF-Independent vulnerability. Cancer Discov. American Association for Cancer Research. 2020;10:348\u201350. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1525."},{"issue":"7","key":"986_CR59","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41556-023-01170-4","volume":"25","author":"T Zhang","year":"2023","unstructured":"Zhang T, Xu D, Liu J, Wang M, Duan L-J, Liu M, et al. Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation. Nat Cell Biol. 2023;25(7):950\u201362. https:\/\/doi.org\/10.1038\/s41556-023-01170-4.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"986_CR60","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41419-024-06844-x","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Li H, Liu X, Yin T, Li T, Zheng M, et al. VHL suppresses UBE3B-mediated breast tumor growth and metastasis. Cell Death Dis. 2024;15(6):446. https:\/\/doi.org\/10.1038\/s41419-024-06844-x.","journal-title":"Cell Death Dis"},{"issue":"10","key":"986_CR61","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ncb1781","volume":"10","author":"VC Chitalia","year":"2008","unstructured":"Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, et al. Jade-1 inhibits wnt signalling by ubiquitylating beta-catenin and mediates wnt pathway inhibition by pVHL. Nat Cell Biol. 2008;10(10):1208\u201316. https:\/\/doi.org\/10.1038\/ncb1781.","journal-title":"Nat Cell Biol"},{"key":"986_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pbiomolbio.2018.12.005","volume":"145","author":"S Shafique","year":"2019","unstructured":"Shafique S, Rashid S. Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and \u03b2-catenin regulation. Prog Biophys Mol Biol. 2019;145:65\u201377. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2018.12.005.","journal-title":"Prog Biophys Mol Biol"},{"issue":"4","key":"986_CR63","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/0008-5472.can-03-0884","volume":"64","author":"MI Zhou","year":"2004","unstructured":"Zhou MI, Wang H, Foy RL, Ross JJ, Cohen HT. Tumor suppressor von Hippel-Lindau (VHL) stabilization of jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res. 2004;64(4):1278\u201386. https:\/\/doi.org\/10.1158\/0008-5472.can-03-0884.","journal-title":"Cancer Res"},{"issue":"17","key":"986_CR64","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1158\/0008-5472.CAN-12-4707","volume":"73","author":"L Zeng","year":"2013","unstructured":"Zeng L, Bai M, Mittal AK, El-Jouni W, Zhou J, Cohen DM, et al. Candidate tumor suppressor and pVHL partner jade-1 binds and inhibits AKT in renal cell carcinoma. Cancer Res. 2013;73(17):5371\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4707.","journal-title":"Cancer Res"},{"issue":"43","key":"986_CR65","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785\u201393. https:\/\/doi.org\/10.1038\/sj.onc.1206792.","journal-title":"Oncogene"},{"issue":"16","key":"986_CR66","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/onc.2009.35","volume":"28","author":"Y Guo","year":"2009","unstructured":"Guo Y, Schoell MC, Freeman RS. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene. 2009;28(16):1864\u201374. https:\/\/doi.org\/10.1038\/onc.2009.35.","journal-title":"Oncogene"},{"key":"986_CR67","doi-asserted-by":"publisher","unstructured":"Xue J, Lv D-D, Jiao S, Zhao W, Li X, Sun H, et al. pVHL mediates K63-linked ubiquitination of nCLU. PLoS One. 2012;7(4):e35848. https:\/\/doi.org\/10.1371\/journal.pone.0035848.","DOI":"10.1371\/journal.pone.0035848"},{"key":"986_CR68","doi-asserted-by":"publisher","unstructured":"Fang W, Liao C, Shi R, Simon JM, Ptacek TS, Zurlo G, et al. ZHX2 promotes HIF1\u03b1 oncogenic signaling in triple-negative breast cancer. Elife. 2021;10:e70412. https:\/\/doi.org\/10.7554\/eLife.70412.","DOI":"10.7554\/eLife.70412"},{"issue":"5","key":"986_CR69","doi-asserted-by":"publisher","first-page":"108430","DOI":"10.1016\/j.jbc.2025.108430","volume":"301","author":"X Li","year":"2025","unstructured":"Li X, Cho YS, Han Y, Zhou M, Liu Y, Yang Y, et al. The hippo pathway effector YAP inhibits NF-\u03baB signaling and ccRCC growth by opposing ZHX2. J Biol Chem. 2025;301(5):108430. https:\/\/doi.org\/10.1016\/j.jbc.2025.108430.","journal-title":"J Biol Chem"},{"issue":"5","key":"986_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41419-020-2541-x","volume":"11","author":"L Zhu","year":"2020","unstructured":"Zhu L, Ding R, Yan H, Zhang J, Lin Z. ZHX2 drives cell growth and migration via activating MEK\/ERK signal and induces sunitinib resistance by regulating the autophagy in clear cell renal cell carcinoma. Cell Death Dis. 2020;11(5):337. https:\/\/doi.org\/10.1038\/s41419-020-2541-x.","journal-title":"Cell Death Dis"},{"issue":"19","key":"986_CR71","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.3390\/cancers13194801","volume":"13","author":"R Hoefflin","year":"2021","unstructured":"Hoefflin R, Harlander S, Abhari BA, Peighambari A, Adlesic M, Seidel P, et al. Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in HIF-2\u03b1 inhibitor-resistant clear cell renal cell carcinoma. Cancers (Basel). 2021;13(19):4801. https:\/\/doi.org\/10.3390\/cancers13194801.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"986_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3892\/ol.2021.12640","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhu L, Xue S, Shi J, He C, Zhang Q. Novel VHL substrate targets SFMBT1 and ZHX2 may be important prognostic predictors in patients with ccRCC. Oncol Lett. 2021;21(5):379. https:\/\/doi.org\/10.3892\/ol.2021.12640.","journal-title":"Oncol Lett"},{"issue":"5","key":"986_CR73","first-page":"1803","volume":"11","author":"VJ Lazaro-Camp","year":"2021","unstructured":"Lazaro-Camp VJ, Salari K, Meng X, Yang S. SETDB1 in cancer: overexpression and its therapeutic implications. Am J Cancer Res. 2021;11(5):1803\u201327.","journal-title":"Am J Cancer Res"},{"issue":"12","key":"986_CR74","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.7150\/ijbs.97503","volume":"20","author":"J Tian","year":"2024","unstructured":"Tian J, Gao J, Cheng C, Xu Z, Chen X, Wu Y, et al. NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression. Int J Biol Sci. 2024;20(12):4853\u201371. https:\/\/doi.org\/10.7150\/ijbs.97503.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"986_CR75","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cac2.12523","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, Shi J, Lv Q, Tan D, Zhao C, Xiong Z, et al. NAT10-mediated ac4C-modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear-cell renal cell carcinoma by attenuating YWHAE-driven cytoplasmic retention of YAP1. Cancer Commun (Lond). London, England. 2024;44(3):361\u201383. https:\/\/doi.org\/10.1002\/cac2.12523.","journal-title":"Cancer Commun (Lond)"},{"key":"986_CR76","doi-asserted-by":"publisher","first-page":"111700","DOI":"10.1016\/j.cellsig.2025.111700","volume":"130","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhang S, Zeng B, Lv J, Shi B, Liu Y, et al. PUS1 facilitates cell migration in clear cell renal cell carcinoma through the promotion of mRNA pseudouridylation and the stabilization of the SMOX gene. Cell Signal. 2025;130:111700. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111700.","journal-title":"Cell Signal"},{"issue":"11","key":"986_CR77","first-page":"3014","volume":"62","author":"RS Bindra","year":"2002","unstructured":"Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002;62(11):3014\u201319.","journal-title":"Cancer Res"},{"issue":"9","key":"986_CR78","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671\u201382. https:\/\/doi.org\/10.1038\/nrc2399.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"986_CR79","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ejca.2005.08.004","volume":"41","author":"A Sala","year":"2005","unstructured":"Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer. 2005;41(16):2479\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.004.","journal-title":"Eur J Cancer"},{"issue":"23","key":"986_CR80","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1101\/gad.12.23.3663","volume":"12","author":"G Levkowitz","year":"1998","unstructured":"Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. C-Cbl\/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12(23):3663\u201374. https:\/\/doi.org\/10.1101\/gad.12.23.3663.","journal-title":"Genes Dev"},{"key":"986_CR81","doi-asserted-by":"publisher","unstructured":"Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. Bmjonc [Internet]. BMJ Publishing Group Ltd. 2024 [cited 2025 Sept 28];3(1):e000154. https:\/\/doi.org\/10.1136\/bmjonc-2023-000154.","DOI":"10.1136\/bmjonc-2023-000154"},{"issue":"9","key":"986_CR82","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1073\/pnas.052090899","volume":"99","author":"JE Egan","year":"2002","unstructured":"Egan JE, Hall AB, Yatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human sprouty proteins. Proc Natl Acad Sci USA. 2002;99(9):6041\u201346. https:\/\/doi.org\/10.1073\/pnas.052090899.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"986_CR83","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/cncr.22677","volume":"109","author":"AJ Pantuck","year":"2007","unstructured":"Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109(11):2257\u201367. https:\/\/doi.org\/10.1002\/cncr.22677.","journal-title":"Cancer"},{"issue":"1","key":"986_CR84","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"986_CR85","doi-asserted-by":"publisher","unstructured":"Ferle PE, Krause N, Koliwer J, V\u00f6lker JM, Becker F, Hillebrand A, et al. The lactate sensor NDRG3 decelerates ER-to-golgi transport through interaction with the long isoform of syntaxin-5. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences. 2025;122(47):e2511307122. https:\/\/doi.org\/10.1073\/pnas.2511307122.","DOI":"10.1073\/pnas.2511307122"},{"issue":"5","key":"986_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s12276-018-0089-y","volume":"50","author":"GY Lee","year":"2018","unstructured":"Lee GY, Shin S-H, Shin H-W, Chun Y-S, Park J-W. NDRG3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors. Exp Mol Med. 2018;50(5):61. https:\/\/doi.org\/10.1038\/s12276-018-0089-y.","journal-title":"Exp Mol Med"},{"key":"986_CR87","doi-asserted-by":"publisher","unstructured":"Couchman JR, Austria MR, Woods A. Fibronectin-cell interactions. J Invest Dermatol. 1990;94(6):s7\u201314. https:\/\/doi.org\/10.1111\/1523-1747.ep12874973.","DOI":"10.1111\/1523-1747.ep12874973"},{"issue":"7","key":"986_CR88","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/s1097-2765(00)80096-9","volume":"1","author":"M Ohh","year":"1998","unstructured":"Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998;1(7):959\u201368. https:\/\/doi.org\/10.1016\/s1097-2765(00)80096-9.","journal-title":"Mol Cell"},{"issue":"7","key":"986_CR89","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.onc.1210709","volume":"27","author":"G Kurban","year":"2008","unstructured":"Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y, et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene. 2008;27(7):1004\u201312. https:\/\/doi.org\/10.1038\/sj.onc.1210709.","journal-title":"Oncogene"},{"issue":"47","key":"986_CR90","doi-asserted-by":"publisher","first-page":"43611","DOI":"10.1074\/jbc.M107880200","volume":"276","author":"H Okuda","year":"2001","unstructured":"Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem. 2001;276(47):43611\u201317. https:\/\/doi.org\/10.1074\/jbc.M107880200.","journal-title":"J Biol Chem"},{"issue":"9","key":"986_CR91","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1242\/dev.042804","volume":"137","author":"S Duchi","year":"2010","unstructured":"Duchi S, Fagnocchi L, Cavaliere V, Hsouna A, Gargiulo G, Hsu T. Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development. 2010;137(9):1493\u2013503. https:\/\/doi.org\/10.1242\/dev.042804.","journal-title":"Development"},{"key":"986_CR92","doi-asserted-by":"publisher","unstructured":"Wolf MM, Madden MZ, Arner EN, Bader JE, Ye X, Vlach L, et al. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. J Clin Invest. 2024;134(8):e173934. https:\/\/doi.org\/10.1172\/JCI173934.","DOI":"10.1172\/JCI173934"},{"issue":"4","key":"986_CR93","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo L, Chen Q, Qiu J, Yu Y, Klapholz M, Budinich KA, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity. 2022;55(4):671\u201385.e10. https:\/\/doi.org\/10.1016\/j.immuni.2022.03.007.","journal-title":"Immunity"},{"key":"986_CR94","doi-asserted-by":"publisher","first-page":"101150","DOI":"10.1016\/j.drup.2024.101150","volume":"77","author":"X Zeng","year":"2024","unstructured":"Zeng X, Chen Z, Zhu Y, Liu L, Zhang Z, Xiao Y, et al. O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma. Drug Resist Updat. 2024;77:101150. https:\/\/doi.org\/10.1016\/j.drup.2024.101150.","journal-title":"Drug Resist Updat"},{"issue":"46","key":"986_CR95","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41388-023-02842-z","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu X, Wang M, Wang Y, Wang S, Jin L, et al. UBE3B promotes breast cancer progression by antagonizing HIF-2\u03b1 degradation. Oncogene. 2023;42(46):3394\u2013406. https:\/\/doi.org\/10.1038\/s41388-023-02842-z.","journal-title":"Oncogene"},{"issue":"6","key":"986_CR96","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1074\/jbc.M116.766824","volume":"292","author":"A Braganza","year":"2017","unstructured":"Braganza A, Li J, Zeng X, Yates NA, Dey NB, Andrews J, et al. UBE3B is a Calmodulin-regulated, mitochondrion-associated E3 ubiquitin ligase. J Biol Chem. 2017;292(6):2470\u201384. https:\/\/doi.org\/10.1074\/jbc.M116.766824.","journal-title":"J Biol Chem"},{"issue":"1","key":"986_CR97","doi-asserted-by":"publisher","first-page":"6316","DOI":"10.1038\/s41467-020-20107-1","volume":"11","author":"K Li","year":"2020","unstructured":"Li K, Wang F, Yang Z-N, Zhang T-T, Yuan Y-F, Zhao C-X, et al. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Nat Commun. 2020;11(1):6316. https:\/\/doi.org\/10.1038\/s41467-020-20107-1.","journal-title":"Nat Commun"},{"issue":"42","key":"986_CR98","doi-asserted-by":"publisher","first-page":"39887","DOI":"10.1074\/jbc.M205040200","volume":"277","author":"MI Zhou","year":"2002","unstructured":"Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein jade-1. J Biol Chem. 2002;277(42):39887\u201398. https:\/\/doi.org\/10.1074\/jbc.M205040200.","journal-title":"J Biol Chem"},{"issue":"34","key":"986_CR99","doi-asserted-by":"publisher","first-page":"16997","DOI":"10.1073\/pnas.1900748116","volume":"116","author":"S Li","year":"2019","unstructured":"Li S, Rodriguez J, Li W, Bullova P, Fell SM, Surova O, et al. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proc Natl Acad Sci USA. 2019;116(34):16997\u20137006. https:\/\/doi.org\/10.1073\/pnas.1900748116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"986_CR100","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1084\/jem.20150477","volume":"213","author":"ARD Delbridge","year":"2016","unstructured":"Delbridge ARD, Pang SHM, Vandenberg CJ, Grabow S, Aubrey BJ, Tai L, et al. RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. J Exp Med. 2016;213(10):2039\u201348. https:\/\/doi.org\/10.1084\/jem.20150477.","journal-title":"The J Exp Med"},{"issue":"2","key":"986_CR101","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2353\/ajpath.2006.050867","volume":"168","author":"E Nakamura","year":"2006","unstructured":"Nakamura E, Abreu-E-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol. 2006;168(2):574\u201384. https:\/\/doi.org\/10.2353\/ajpath.2006.050867.","journal-title":"Am J Pathol"},{"issue":"4","key":"986_CR102","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/cancers14040961","volume":"14","author":"PH Hoang","year":"2022","unstructured":"Hoang PH, Landi MT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors. Cancers (Basel). 2022;14(4):961. https:\/\/doi.org\/10.3390\/cancers14040961.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"986_CR103","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0169-5002(02)00506-8","volume":"39","author":"S Miyakis","year":"2003","unstructured":"Miyakis S, Liloglou T, Kearney S, Xinarianos G, Spandidos DA, Field JK. Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25-26 in non-small cell lung carcinomas. Lung Cancer. Amsterdam, Netherlands. 2003;39(3):273\u201377. https:\/\/doi.org\/10.1016\/s0169-5002(02)00506-8.","journal-title":"Lung Cancer"},{"issue":"6","key":"986_CR104","first-page":"1599","volume":"9","author":"Y Sekido","year":"1994","unstructured":"Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, et al. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene. 1994;9(6):1599\u2013604.","journal-title":"Oncogene"},{"issue":"15","key":"986_CR105","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1158\/0008-5472.CAN-05-1128","volume":"65","author":"N Zanesi","year":"2005","unstructured":"Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, Valtieri M, et al. Lung cancer susceptibility in fhit-deficient mice is increased by vhl haploinsufficiency. Cancer Res. 2005;65(15):6576\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1128.","journal-title":"Cancer Res"},{"issue":"17","key":"986_CR106","first-page":"4894","volume":"60","author":"L Girard","year":"2000","unstructured":"Girard L, Z\u00f6chbauer-M\u00fcller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000;60(17):4894\u2013906.","journal-title":"Cancer Res"},{"issue":"7","key":"986_CR107","first-page":"1949","volume":"60","author":"B Wistuba II","year":"2000","unstructured":"Wistuba B II, Virmani C, Mele AK, Milchgrub G, Girard SL, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic\/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60(7):1949\u201360.","journal-title":"Cancer Res"},{"issue":"13","key":"986_CR108","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.4161\/cc.10.13.16307","volume":"10","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. Loss of either hypoxia inducible factor 1 or 2 promotes lung cancer cell colonization. Cell Cycle. Georgetown, Tex. 2011;10(13):2233\u201334. https:\/\/doi.org\/10.4161\/cc.10.13.16307.","journal-title":"Cell Cycle"},{"issue":"10","key":"986_CR109","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.febslet.2012.04.009","volume":"586","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. Knockdown of von Hippel-Lindau protein decreases lung cancer cell proliferation and colonization. FEBS Lett. 2012;586(10):1510\u201315. https:\/\/doi.org\/10.1016\/j.febslet.2012.04.009.","journal-title":"FEBS Lett"},{"issue":"4","key":"986_CR110","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.21873\/anticanres.14140","volume":"40","author":"T Shukuya","year":"2020","unstructured":"Shukuya T, Oyanagi J, Serizawa M, Watanabe M, Yamamoto N, Koh Y. Hypoxia inducible factor-1\u03b1 inhibition in Von Hippel lindau-mutant malignant pleural mesothelioma cells. Anticancer Res. International Institute of Anticancer Research. 2020;40(4):1867\u201374. https:\/\/doi.org\/10.21873\/anticanres.14140.","journal-title":"Anticancer Res. Int Inst Anticancer Res"},{"key":"986_CR111","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.humpath.2018.07.033","volume":"83","author":"A Smith-Hannah","year":"2019","unstructured":"Smith-Hannah A, Naous R. Primary peritoneal epithelioid mesothelioma of clear cell type with a novel VHL gene mutation: a case report. Hum Pathol. 2019;83:199\u2013203. https:\/\/doi.org\/10.1016\/j.humpath.2018.07.033.","journal-title":"Hum Pathol"},{"issue":"5","key":"986_CR112","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/gcc.23119","volume":"62","author":"M Michal","year":"2023","unstructured":"Michal M, Kravtsov O, Ross JS, Skanderov\u00e1 D, Mart\u00ednek P, Mosaieby E, et al. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features. Genes Chromosomes Cancer. 2023;62(5):267\u201374. https:\/\/doi.org\/10.1002\/gcc.23119.","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"986_CR113","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41418-023-01128-x","volume":"30","author":"J Chen","year":"2023","unstructured":"Chen J, Li M, Liu Y, Guan T, Yang X, Wen Y, et al. PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions. Cell Death Differ. 2023;30(4):1082\u201395. https:\/\/doi.org\/10.1038\/s41418-023-01128-x.","journal-title":"Cell Death Differ"},{"key":"986_CR114","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3892\/ijmm.20.4.605","volume":"20","author":"MK Zia","year":"2007","unstructured":"Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med. 2007;20:605\u201311. https:\/\/doi.org\/10.3892\/ijmm.20.4.605.","journal-title":"Int J Mol Med"},{"key":"986_CR115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mce.2017.01.019","volume":"443","author":"E Baldini","year":"2017","unstructured":"Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, et al. Deregulated expression of VHL mRNA variants in papillary thyroid cancer. Mol Cell Endocrinol. 2017;443:121\u201327. https:\/\/doi.org\/10.1016\/j.mce.2017.01.019.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"986_CR116","doi-asserted-by":"publisher","first-page":"26","DOI":"10.17305\/bjbms.2022.7850","volume":"23","author":"L Todorovi\u0107","year":"2023","unstructured":"Todorovi\u0107 L, Stanojevi\u0107 B. VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma. Biomol Biomed. 2023;23(1):26\u201336. https:\/\/doi.org\/10.17305\/bjbms.2022.7850.","journal-title":"Biomol Biomed"},{"issue":"2","key":"986_CR117","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1385\/ep:11:2:145","volume":"11","author":"R Hinze","year":"2000","unstructured":"Hinze R, Boltze C, Meye A, Holzhausen H-J, Dralle H, Rath F-W. Expression of the von Hippel-Lindau tumor suppressor gene in Nonneoplastic and neoplastic lesions of the thyroid. Endocr Pathol. 2000;11(2):145\u201356. https:\/\/doi.org\/10.1385\/ep:11:2:145.","journal-title":"Endocr Pathol"},{"issue":"4","key":"986_CR118","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s13577-019-00254-4","volume":"32","author":"C Zang","year":"2019","unstructured":"Zang C, Sun J, Liu W, Chu C, Jiang L, Ge R. miRNA-21 promotes cell proliferation and invasion via VHL\/PI3K\/AKT in papillary thyroid carcinoma. Hum Cell. 2019;32(4):428\u201336. https:\/\/doi.org\/10.1007\/s13577-019-00254-4.","journal-title":"Hum Cell"},{"issue":"2","key":"986_CR119","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12032-017-1066-3","volume":"35","author":"L Todorovi\u0107","year":"2018","unstructured":"Todorovi\u0107 L, Stanojevi\u0107 B, Mandu\u0161i\u0107 V, Petrovi\u0107 N, \u017divaljevi\u0107 V, Paunovi\u0107 I, et al. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters. Med Oncol. Northwood, London, England. 2018;35(2):17. https:\/\/doi.org\/10.1007\/s12032-017-1066-3.","journal-title":"Med Oncol"},{"issue":"4","key":"986_CR120","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1677\/ERC-08-0297","volume":"16","author":"AM Schmitt","year":"2009","unstructured":"Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Kl\u00f6ppel G, et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr-Relat Cancer. 2009;16(4):1219\u201327. https:\/\/doi.org\/10.1677\/ERC-08-0297.","journal-title":"Endocr-Relat Cancer"},{"key":"986_CR121","doi-asserted-by":"publisher","unstructured":"Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, et al. The VHL\/HIF Axis in the development and treatment of pheochromocytoma\/paraganglioma. Front Endocrinol [Internet]. Frontiers. 2020 [cited 2026 Mar 2];11. https:\/\/doi.org\/10.3389\/fendo.2020.586857.","DOI":"10.3389\/fendo.2020.586857"},{"key":"986_CR122","doi-asserted-by":"publisher","unstructured":"Perona-Moratalla AB, Carri\u00f3n B, de las HK, Arias-Salazar L, Y\u00e9lamos-Sanz B, Segura T, et al. Dual inhibition of HIF-1\u03b1 and HIF-2\u03b1 as a promising treatment for VHL-Associated hemangioblastomas: a pilot study using patient-derived primary cell cultures. Biomedicines [Internet]. Multidisciplinary Digital Publishing Institute. 2025 [cited 2026 Mar 9];13. https:\/\/doi.org\/10.3390\/biomedicines13051234.","DOI":"10.3390\/biomedicines13051234"},{"issue":"3","key":"986_CR123","first-page":"1058","volume":"9","author":"S-J Li","year":"2017","unstructured":"Li S-J, Liu H-L, Tang S-L, Li X-J, Wang X-Y. MicroRNA-150 regulates glycolysis by targeting von Hippel-Lindau in glioma cells. Am J Transl Res. 2017;9(3):1058\u201366.","journal-title":"Am J Transl Res"},{"issue":"1","key":"986_CR124","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41420-024-01919-2","volume":"10","author":"Z Shen","year":"2024","unstructured":"Shen Z, Dong T, Yong H, Deng C, Chen C, Chen X, et al. FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation. Cell Death Discov. 2024;10(1):151. https:\/\/doi.org\/10.1038\/s41420-024-01919-2.","journal-title":"Cell Death Discov"},{"key":"986_CR125","doi-asserted-by":"publisher","unstructured":"Zhu W, Krishna S, Garcia C, Lin C-C, Mitchell BD, Scott KL, et al. Daam2 driven degradation of VHL promotes gliomagenesis. Elife. 2017;6:e31926. https:\/\/doi.org\/10.7554\/eLife.31926.","DOI":"10.7554\/eLife.31926"},{"issue":"3","key":"986_CR126","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3816\/CLM.2009.n.047","volume":"9","author":"E Hatzimichael","year":"2009","unstructured":"Hatzimichael E, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, et al. Von Hippel-Lindau Methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma. 2009;9(3):239\u201342. https:\/\/doi.org\/10.3816\/CLM.2009.n.047.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"986_CR127","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3349\/ymj.2020.61.1.20","volume":"61","author":"L Chen","year":"2020","unstructured":"Chen L, Zhan CZ, Wang T, You H, Yao R. Curcumin inhibits the proliferation, migration, invasion, and apoptosis of diffuse large B-Cell lymphoma cell line by regulating MiR-21\/VHL Axis. Yonsei Med J. 2020;61(1):20\u201329. https:\/\/doi.org\/10.3349\/ymj.2020.61.1.20.","journal-title":"Yonsei Med J"},{"issue":"4","key":"986_CR128","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/1535-7163.MCT-16-0606","volume":"16","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang S, Wu Y, Ren Y, Li Z, Yao X, et al. Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21\/\u03b2-catenin Axis with HJC0152. Mol Cancer Ther. 2017;16(4):578\u201390. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0606.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"986_CR129","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12885-017-3364-8","volume":"17","author":"H Hasegawa","year":"2017","unstructured":"Hasegawa H, Kusumi Y, Asakawa T, Maeda M, Oinuma T, Furusaka T, et al. Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium. BMC Cancer. 2017;17(1):381. https:\/\/doi.org\/10.1186\/s12885-017-3364-8.","journal-title":"BMC Cancer"},{"issue":"28","key":"986_CR130","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863\u201371. https:\/\/doi.org\/10.1200\/JCO.2018.78.5204.","journal-title":"J Clin Oncol"},{"issue":"2","key":"986_CR131","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3892\/ol.2020.11733","volume":"20","author":"J Wang","year":"2020","unstructured":"Wang J, Wang Y, Xing P, Liu Q, Zhang C, Sui Y, et al. Development and validation of a hypoxia-related prognostic signature for breast cancer. Oncol Lett. 2020;20(2):1906\u201314. https:\/\/doi.org\/10.3892\/ol.2020.11733.","journal-title":"Oncol Lett"},{"issue":"4","key":"986_CR132","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.886","volume":"194","author":"A Barghorn","year":"2001","unstructured":"Barghorn A, Komminoth P, Bachmann D, R\u00fctimann K, Saremaslani P, Muletta-Feurer S, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol. 2001;194(4):451\u201358. https:\/\/doi.org\/10.1002\/path.886.","journal-title":"The J Pathol"},{"issue":"5","key":"986_CR133","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2967\/jnumed.120.245613","volume":"61","author":"D Ta\u00efeb","year":"2020","unstructured":"Ta\u00efeb D, Pacak K. Genetic determinants of pheochromocytoma and Paraganglioma imaging phenotypes. J Nucl Med. 2020;61(5):643\u201345. https:\/\/doi.org\/10.2967\/jnumed.120.245613.","journal-title":"J Nucl Med"},{"issue":"1","key":"986_CR134","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcancer.2008.11.009","volume":"19","author":"GL Semenza","year":"2009","unstructured":"Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009;19(1):12\u201316. https:\/\/doi.org\/10.1016\/j.semcancer.2008.11.009.","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"986_CR135","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/diagnostics14171909","volume":"14","author":"L G\u00f3mez-Virgilio","year":"2024","unstructured":"G\u00f3mez-Virgilio L, Velazquez-Paniagua M, Cuazozon-Ferrer L, Silva-Lucero M-C, Gutierrez-Malacara A-I, Padilla-Mendoza J-R, et al. Genetics, pathophysiology, and current challenges in Von Hippel-Lindau disease therapeutics. Diagn [Internet]. Multidisciplinary Digital Publishing Institute. 2024 [cited 2026 Mar 9];14(17):1909. https:\/\/doi.org\/10.3390\/diagnostics14171909.","journal-title":"Diagn [Internet]"},{"issue":"20","key":"986_CR136","doi-asserted-by":"publisher","first-page":"9979","DOI":"10.3390\/ijms26209979","volume":"26","author":"I Flores","year":"2025","unstructured":"Flores I, Salazar A, de la CVP, Mena-Guerrero T, Cossio JAN, Figueroa R, et al. Von Hippel-Lindau\/Hypoxia inducible factor axis in Glioblastoma. Int J Mol Sci [Internet]. 2025 [cited 2026 Mar 2];26(20):9979. https:\/\/doi.org\/10.3390\/ijms26209979.","journal-title":"Int J Mol Sci [Internet]"},{"key":"986_CR137","doi-asserted-by":"publisher","first-page":"1236271","DOI":"10.3389\/fcell.2023.1236271","volume":"11","author":"S Kumari","year":"2023","unstructured":"Kumari S, Kumar P. Identification and characterization of putative biomarkers and therapeutic axis in glioblastoma multiforme microenvironment. Front Cell Dev Biol. 2023;11:1236271. https:\/\/doi.org\/10.3389\/fcell.2023.1236271.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"986_CR138","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/neuonc\/nos122","volume":"14","author":"L C","year":"2012","unstructured":"Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A et al. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1\u03b1\/VEGF and \u03b2-catenin\/tcf-4 signaling. Neuro-Oncol [Internet]. 2012 [cited 2026 Mar 7];14(8):1026\u201336. https:\/\/doi.org\/10.1093\/neuonc\/nos122.","journal-title":"Neuro-Oncol [Internet]"},{"issue":"1","key":"986_CR139","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3892\/mmr.2015.4537","volume":"13","author":"B X","year":"2016","unstructured":"Xiao B, Zhou X, Ye M, Lv S, Wu M, Liao C et al. MicroRNA\u2011566 modulates vascular endothelial growth factor by targeting Von Hippel\u2011Landau in human glioblastoma in vitro and in vivo. Mol Med Rep [Internet]. 2016 [cited 2026 Mar 7];13(1):379\u201385. https:\/\/doi.org\/10.3892\/mmr.2015.4537.","journal-title":"Mol Med Rep [Internet]"},{"issue":"8","key":"986_CR140","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/1878-0261.12744","volume":"14","author":"P Blecua","year":"2020","unstructured":"Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616\u201339. https:\/\/doi.org\/10.1002\/1878-0261.12744.","journal-title":"Mol Oncol"},{"issue":"10","key":"986_CR141","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/annonc\/mdn374","volume":"19","author":"K Amara","year":"2008","unstructured":"Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 2008;19(10):1774\u201386. https:\/\/doi.org\/10.1093\/annonc\/mdn374.","journal-title":"Ann Oncol"},{"key":"986_CR142","doi-asserted-by":"publisher","unstructured":"Chen H, Hu W, Ma C, Zhang M, Yang F, Zeng P. Case report: a familial hematological pedigree reveals VHL germline mutation as a principal predisposition factor with additional mutations modulating phenotypic heterogeneity. Front Oncol [Internet]. Frontiers. 2025 [cited 2026 Mar 2];15. https:\/\/doi.org\/10.3389\/fonc.2025.1630715.","DOI":"10.3389\/fonc.2025.1630715"},{"issue":"9","key":"986_CR143","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.oraloncology.2014.06.007","volume":"50","author":"S Z","year":"2014","unstructured":"Zhang S, Zhou X, Wang B, Zhang K, Liu S, Yue K et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma. Oral Oncol [Internet]. 2014 [cited 2026 Mar 7];50(9):809\u201317. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.06.007.","journal-title":"Oral Oncol [Internet]"},{"issue":"3","key":"986_CR144","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/cncr.23200","volume":"112","author":"T A","year":"2008","unstructured":"Asakawa T, Esumi M, Endo S, Kida A, Ikeda M. Tongue cancer patients have a high frequency of allelic loss at the von Hippel-Lindau gene and other loci on 3p. Cancer [Internet]. 2008 [cited 2026 Mar 7];112(3):527\u201334. https:\/\/doi.org\/10.1002\/cncr.23200.","journal-title":"Cancer [Internet]"},{"issue":"10373","key":"986_CR145","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. London, England. 2023;401(10373):269\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0.","journal-title":"Lancet"},{"key":"986_CR146","doi-asserted-by":"publisher","unstructured":"Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, et al. Phase 1B study of momelotinib combined with trametinib in metastatic, Kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer. 2018;19(6):e853\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2018.07.004.","DOI":"10.1016\/j.cllc.2018.07.004"},{"issue":"1","key":"986_CR147","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmet.2017.06.006","volume":"26","author":"EA Oral","year":"2017","unstructured":"Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, et al. Inhibition of iKK\u025b and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab. 2017;26(1):157\u201370.e7. https:\/\/doi.org\/10.1016\/j.cmet.2017.06.006.","journal-title":"Cell Metab"},{"issue":"4","key":"986_CR148","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","volume":"16","author":"B Melichar","year":"2015","unstructured":"Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, et al. Safety and activity of alisertib, an investigational aurora kinase a inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16(4):395\u2013405. https:\/\/doi.org\/10.1016\/S1470-2045(15)70051-3.","journal-title":"The Lancet Oncol"},{"issue":"6","key":"986_CR149","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaoncol.2022.7949","volume":"9","author":"TC Haddad","year":"2023","unstructured":"Haddad TC, Suman VJ, D\u2019Assoro AB, Carter JM, Giridhar KV, McMenomy BP, et al. Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial. JAMA Oncol. 2023;9(6):815\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7949.","journal-title":"JAMA Oncol"},{"key":"986_CR150","doi-asserted-by":"publisher","unstructured":"Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, et al. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2019;5(1):e183773. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3773.","DOI":"10.1001\/jamaoncol.2018.3773"},{"key":"986_CR151","doi-asserted-by":"publisher","unstructured":"O\u2019Shaughnessy J, McIntyre K, Wilks S, Ma L, Block M, Andorsky D, et al. Efficacy and safety of weekly paclitaxel with or without oral alisertib in patients with metastatic breast cancer: a randomized clinical trial. JAMA Netw Open. 2021;4(4):e214103. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.4103.","DOI":"10.1001\/jamanetworkopen.2021.4103"},{"issue":"8","key":"986_CR152","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/cancers16081456","volume":"16","author":"SL Davis","year":"2024","unstructured":"Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, et al. A phase ib expansion cohort evaluating aurora a kinase inhibitor alisertib and dual TORC1\/2 inhibitor sapanisertib in patients with advanced solid tumors. Cancers (Basel). 2024;16(8):1456. https:\/\/doi.org\/10.3390\/cancers16081456.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"986_CR153","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","volume":"23","author":"CD Britten","year":"2017","unstructured":"Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, et al. A phase I study of ABC294640, a first-in-Class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(16):4642\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2363.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"986_CR154","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00277-022-05056-7","volume":"102","author":"Y Kang","year":"2023","unstructured":"Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, et al. Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and\/or refractory multiple myeloma. Ann Hematol. 2023;102(2):369\u201383. https:\/\/doi.org\/10.1007\/s00277-022-05056-7.","journal-title":"Ann Hematol"},{"issue":"18","key":"986_CR155","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1200\/JCO.2004.10.155","volume":"22","author":"GV Kondagunta","year":"2004","unstructured":"Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22(18):3720\u201325. https:\/\/doi.org\/10.1200\/JCO.2004.10.155.","journal-title":"J Clin Oncol"},{"issue":"4","key":"986_CR156","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1634\/theoncologist.2015-0055","volume":"20","author":"A Rao","year":"2015","unstructured":"Rao A, Lauer R. Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist. 2015;20(4):370\u201371. https:\/\/doi.org\/10.1634\/theoncologist.2015-0055.","journal-title":"Oncologist"},{"issue":"1","key":"986_CR157","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13046-022-02352-y","volume":"41","author":"AP Runde","year":"2022","unstructured":"Runde AP, Mack R, Pb SJ, Zhang J. The role of TBK1 in cancer pathogenesis and anticancer immunity. J Exp Clin Cancer Res. 2022;41(1):135. https:\/\/doi.org\/10.1186\/s13046-022-02352-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"986_CR158","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.3082","volume":"19","author":"SM Reilly","year":"2013","unstructured":"Reilly SM, Chiang S-H, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-\u025b improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19(3):313\u201321. https:\/\/doi.org\/10.1038\/nm.3082.","journal-title":"Nat Med"},{"key":"986_CR159","doi-asserted-by":"publisher","first-page":"114895","DOI":"10.1016\/j.bcp.2021.114895","volume":"197","author":"C Bailly","year":"2022","unstructured":"Bailly C. The potential value of amlexanox in the treatment of cancer: molecular targets and therapeutic perspectives. Biochem Pharmacol. 2022;197:114895. https:\/\/doi.org\/10.1016\/j.bcp.2021.114895.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"986_CR160","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers16051050","volume":"16","author":"FZ Asumda","year":"2024","unstructured":"Asumda FZ, Campbell NA, Hassan MA, Fathi R, Vasquez Rico DF, Kiem M, et al. Combined antitumor effect of the serine protease urokinase inhibitor upamostat and the sphingosine kinase 2 inhibitor opaganib on cholangiocarcinoma patient-derived xenografts. Cancers (Basel). 2024;16(5):1050. https:\/\/doi.org\/10.3390\/cancers16051050.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"986_CR161","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2016.01.053","volume":"470","author":"T Ju","year":"2016","unstructured":"Ju T, Gao D, Fang Z. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Bioph Res Co. 2016;470(3):728\u201334. https:\/\/doi.org\/10.1016\/j.bbrc.2016.01.053.","journal-title":"Biochem Bioph Res Co"},{"key":"986_CR162","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3892\/mmr.2018.9038","volume":"18","author":"X-F Ding","year":"2018","unstructured":"Ding X-F, Zhou J, Chen G, Wu Y-L. VHL loss predicts response to Aurora kinase a inhibitor in renal cell carcinoma cells. Mol Med Rep. 2018;18:1206\u201310. https:\/\/doi.org\/10.3892\/mmr.2018.9038.","journal-title":"Mol Med Rep"},{"issue":"7","key":"986_CR163","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41419-022-04973-9","volume":"13","author":"P Li","year":"2022","unstructured":"Li P, Chen T, Kuang P, Liu F, Li Z, Liu F, et al. Aurora-A\/FOXO3A\/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting aurora-A\/SKP2 shows synthetic lethality. Cell Death Dis. 2022;13(7):606. https:\/\/doi.org\/10.1038\/s41419-022-04973-9.","journal-title":"Cell Death Dis"},{"issue":"9","key":"986_CR164","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/sj.onc.1208348","volume":"24","author":"J An","year":"2005","unstructured":"An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene. 2005;24(9):1563\u201370. https:\/\/doi.org\/10.1038\/sj.onc.1208348.","journal-title":"Oncogene"},{"issue":"3","key":"986_CR165","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1042\/BJ20141450","volume":"467","author":"E Bulatov","year":"2015","unstructured":"Bulatov E, Ciulli A. Targeting cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem J. 2015;467(3):365\u201386. https:\/\/doi.org\/10.1042\/BJ20141450.","journal-title":"Biochem J"},{"issue":"9","key":"986_CR166","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1021\/acschembio.9b00505","volume":"14","author":"H Tovell","year":"2019","unstructured":"Tovell H, Testa A, Zhou H, Shpiro N, Crafter C, Ciulli A, et al. Design and characterization of SGK3-PROTAC1, an Isoform specific SGK3 kinase PROTAC degrader. ACS Chem Biol. 2019;14(9):2024\u201334. https:\/\/doi.org\/10.1021\/acschembio.9b00505.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"986_CR167","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10(2):207\u201338. https:\/\/doi.org\/10.1016\/j.apsb.2019.08.001.","journal-title":"Acta Pharm Sin B"},{"key":"986_CR168","doi-asserted-by":"publisher","first-page":"112993","DOI":"10.1016\/j.ejmech.2020.112993","volume":"210","author":"P Mart\u00edn-Acosta","year":"2021","unstructured":"Mart\u00edn-Acosta P, Xiao X. Protacs to address the challenges facing small molecule inhibitors. Eur J Med Chem. 2021;210:112993. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112993.","journal-title":"Eur J Med Chem"},{"key":"986_CR169","doi-asserted-by":"publisher","first-page":"113906","DOI":"10.1016\/j.ejmech.2021.113906","volume":"227","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. Eur J Med Chem. 2022;227:113906. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113906.","journal-title":"Eur J Med Chem"},{"issue":"19","key":"986_CR170","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1039\/d2cs00387b","volume":"51","author":"CJ Diehl","year":"2022","unstructured":"Diehl CJ, Ciulli A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chem Soc Rev. 2022;51(19):8216\u201357. https:\/\/doi.org\/10.1039\/d2cs00387b.","journal-title":"Chem Soc Rev"},{"issue":"3","key":"986_CR171","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543776.2024.2446232","volume":"35","author":"A Urbina","year":"2025","unstructured":"Urbina A, Hallatt AJ, Robertson J, Ciulli A. A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present). Expert Opin Ther Pat. 2025;35(3):197\u2013238. https:\/\/doi.org\/10.1080\/13543776.2024.2446232.","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"986_CR172","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. International ed. in English. 2016;55(2):807\u201310. https:\/\/doi.org\/10.1002\/anie.201507634.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"9","key":"986_CR173","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","volume":"61","author":"CE Powell","year":"2018","unstructured":"Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, et al. Chemically induced degradation of anaplastic lymphoma kinase (ALK). J Med Chem. 2018;61(9):4249\u201355. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01655.","journal-title":"J Med Chem"},{"issue":"1","key":"986_CR174","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13578-022-00936-x","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, Ruan Y, Wang D, Fan J, Luo N, Chen H, et al. VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2\u03b1. Cell Biosci. 2022;12(1):203. https:\/\/doi.org\/10.1186\/s13578-022-00936-x.","journal-title":"Cell Biosci"},{"issue":"1","key":"986_CR175","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","volume":"18","author":"D Mahadevan","year":"2025","unstructured":"Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, et al. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies. J Hematol Oncol. 2025;18(1):98. https:\/\/doi.org\/10.1186\/s13045-025-01753-8.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"986_CR176","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49\u201363. https:\/\/doi.org\/10.1038\/nrm3722.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"986_CR177","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u201308. https:\/\/doi.org\/10.1038\/nm.3048.","journal-title":"Nat Med"},{"issue":"1","key":"986_CR178","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-022-01241-3","volume":"15","author":"S Khan","year":"2022","unstructured":"Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022;15(1):23. https:\/\/doi.org\/10.1186\/s13045-022-01241-3.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"986_CR179","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938\u201347. https:\/\/doi.org\/10.1038\/s41591-019-0668-z.","journal-title":"Nat Med"},{"issue":"1","key":"986_CR180","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13046-025-03635-w","volume":"45","author":"E Valentini","year":"2026","unstructured":"Valentini E, Gentile G, Di Martile M, D\u2019Aguanno S, Brignone M, Di Stefano AM, et al. PROTAC-mediated degradation of bcl-xL potentiates target therapy in preclinical melanoma models. J Exp Clin Cancer Res. 2026;45(1):37. https:\/\/doi.org\/10.1186\/s13046-025-03635-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"986_CR181","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1038\/s41467-025-61242-x","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Santana-Codina N, Yu Q, Poupault C, Campos C, Qin X, et al. De Novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Nat Commun. 2025;16(1):6987. https:\/\/doi.org\/10.1038\/s41467-025-61242-x.","journal-title":"Nat Commun"},{"issue":"10","key":"986_CR182","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/s41417-025-00953-1","volume":"32","author":"N Mahmoud","year":"2025","unstructured":"Mahmoud N, Qin X, Bzeih W, Khabibullin D, Alchoueiry M, Safi S, et al. BCL-xL dependency in chromophobe renal cell carcinoma. Cancer Gene Ther. 2025;32(10):1133\u201343. https:\/\/doi.org\/10.1038\/s41417-025-00953-1.","journal-title":"Cancer Gene Ther"},{"key":"986_CR183","doi-asserted-by":"publisher","unstructured":"Chakraborty S, Morganti C, Pena BR, Zhang H, Verma D, Zaldana K, et al. A STAT3 degrader demonstrates pre-clinical efficacy in Venetoclax resistant acute myeloid leukemia. bioRxiv. 2024;2024.08.05.599788. https:\/\/doi.org\/10.1101\/2024.08.05.599788.","DOI":"10.1101\/2024.08.05.599788"},{"issue":"9","key":"986_CR184","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tips.2024.07.003","volume":"45","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liao X, He H, Guo X, Chen J. Targeting the STAT3 pathway with STAT3 degraders. Trends Pharmacol Sci. 2024;45(9):811\u201323. https:\/\/doi.org\/10.1016\/j.tips.2024.07.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"Supplement 1","key":"986_CR185","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/blood-2024-210301","volume":"144","author":"T Feldman","year":"2024","unstructured":"Feldman T, Marchi E, Smith SD, Olszewski AJ, Huen AO, Epstein-Peterson ZD, et al. Safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, leukemia, and solid tumors. Blood. 2024;144(Supplement 1):4433. https:\/\/doi.org\/10.1182\/blood-2024-210301.","journal-title":"Blood"},{"issue":"11","key":"986_CR186","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer. 2023;9(11):955\u201367. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.010.","journal-title":"Trends Cancer"},{"issue":"23","key":"986_CR187","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.1021\/acs.jmedchem.0c01312","volume":"63","author":"H Chen","year":"2020","unstructured":"Chen H, Smaill JB, Liu T, Ding K, Lu X. Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics. J Med Chem. 2020;63(23):14404\u201324. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01312.","journal-title":"J Med Chem"},{"issue":"1","key":"986_CR188","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","volume":"8","author":"T Yoshinari","year":"2025","unstructured":"Yoshinari T, Nagashima T, Ishioka H, Inamura K, Nishizono Y, Tasaki M, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8(1):254. https:\/\/doi.org\/10.1038\/s42004-025-01662-4.","journal-title":"Commun Chem"},{"key":"986_CR189","doi-asserted-by":"publisher","unstructured":"Park W, Kasi A, Spira AI, Berlin JD, Wang JS, Herzberg B, et al. 608O preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S486\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.675.","DOI":"10.1016\/j.annonc.2024.08.675"},{"issue":"3","key":"986_CR190","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.trecan.2025.02.002","volume":"11","author":"KA Papavassiliou","year":"2025","unstructured":"Papavassiliou KA, Anagnostopoulos N, Papavassiliou AG. Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers. Trends Cancer. 2025;11(3):185\u201387. https:\/\/doi.org\/10.1016\/j.trecan.2025.02.002.","journal-title":"Trends Cancer"},{"issue":"1","key":"986_CR191","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1158\/0008-5472.CAN-25-1141","volume":"86","author":"M Hulse","year":"2026","unstructured":"Hulse M, Wang M, Xu C, Carter J, Agarwal A, Lu L, et al. PRT3789 is a first-in-human SMARCA2-selective degrader that induces synthetic lethality in SMARCA4-mutated cancers. Cancer Res. 2026;86(1):213\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1141.","journal-title":"Cancer Res"},{"key":"986_CR192","doi-asserted-by":"publisher","unstructured":"Guo R, Dowlati A, Dagogo-Jack I, Vibert J, Spira AI, Moreno Garcia V, et al. 603O first clinical results from a phase I trial of PRT3789: a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation. Ann Oncol. 2024;35:S483\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.670.","DOI":"10.1016\/j.annonc.2024.08.670"},{"issue":"9","key":"986_CR193","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1039\/d2cs00148a","volume":"51","author":"I Sosi\u010d","year":"2022","unstructured":"Sosi\u010d I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders. Chem Soc Rev. 2022;51(9):3487\u2013534. https:\/\/doi.org\/10.1039\/d2cs00148a.","journal-title":"Chem Soc Rev"},{"key":"986_CR194","doi-asserted-by":"publisher","first-page":"116041","DOI":"10.1016\/j.ejmech.2023.116041","volume":"265","author":"N Setia","year":"2024","unstructured":"Setia N, Almuqdadi HTA, Abid M. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: from VHL ligands to VHL-based degraders. Eur J Med Chem. 2024;265:116041. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116041.","journal-title":"Eur J Med Chem"},{"issue":"10","key":"986_CR195","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","volume":"60","author":"D Zaidman","year":"2020","unstructured":"Zaidman D, Prilusky J, London N. PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes. J Chem Inf Model. 2020;60(10):4894\u2013903. https:\/\/doi.org\/10.1021\/acs.jcim.0c00589.","journal-title":"J Chem Inf Model"},{"issue":"5","key":"986_CR196","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2174\/1871520622666220617103126","volume":"23","author":"I Passi","year":"2023","unstructured":"Passi I, Billowria K, Kumar B, Chawla PA. Tivozanib: a new hope for treating renal cell carcinoma. Anticancer Agents Med Chem. 2023;23(5):562\u201370. https:\/\/doi.org\/10.2174\/1871520622666220617103126.","journal-title":"Anticancer Agents Med Chem"},{"key":"986_CR197","doi-asserted-by":"publisher","first-page":"870396","DOI":"10.3389\/fonc.2022.870396","volume":"12","author":"Y Xiang","year":"2022","unstructured":"Xiang Y, Zheng G, Zhong J, Sheng J, Qin H. Advances in renal cell carcinoma drug resistance models. Front Oncol. 2022;12:870396. https:\/\/doi.org\/10.3389\/fonc.2022.870396.","journal-title":"Front Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00986-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:33:06Z","timestamp":1788957186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00986-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}